Highly Active Anti-retroviral therapy (HAART):
Can achieve remission in 60-90% remission in stage T0 disease
Can combine with chemotherapy
Chemotherapy:
First-line: Pegylated liposomal doxorubicin (PLD) 20mg/m2 every three weeks (unless cardiac contraindication)
Second-line: Vinblastine, Bleomycin, Paclitaxel, Etoposide, Gemcitabine
Cutaneous Specific Treatment:
Alitretinoin (9-cis-retinoic acid) topical gel 0.1% FDA-approved for cutaneous AIDS-associated<unk> 
Intralesion Injection: Vinblastine or Bleomycin or INF-alpha
Vinblastine 0.2 – 0.3mg/mL solution with a volume of 1 mL per 0.5 cm2 of lesion
IFNa - FDA approved for AIDS-associated<unk> 
Radiation Therapy
30 Gy in 15 daily 2 Gy fractions
Other Drug Trials:
Bevacizumab - an anti-VEGF-A
Imatinib - monoclonal antibody tyrosine kinase receptor
Steroids
Associated with generation and exacerbation of<unk> 
Important implications because of the high use of steroids in this patient population (HIV/AIDS, transplant)
Once steroids are removed,<unk>  can regress
Can achieve remission in 60-90% remission in stage T0 disease
Can combine with chemotherapy
First-line: Pegylated liposomal doxorubicin (PLD) 20mg/m2 every three weeks (unless cardiac contraindication)
Second-line: Vinblastine, Bleomycin, Paclitaxel, Etoposide, Gemcitabine
Alitretinoin (9-cis-retinoic acid) topical gel 0.1% FDA-approved for cutaneous AIDS-associated<unk> 
Intralesion Injection: Vinblastine or Bleomycin or INF-alpha
Vinblastine 0.2 – 0.3mg/mL solution with a volume of 1 mL per 0.5 cm2 of lesion
IFNa - FDA approved for AIDS-associated<unk> 
30 Gy in 15 daily 2 Gy fractions
Bevacizumab - an anti-VEGF-A
Imatinib - monoclonal antibody tyrosine kinase receptor
Associated with generation and exacerbation of<unk> 
Important implications because of the high use of steroids in this patient population (HIV/AIDS, transplant)
Once steroids are removed,<unk>  can regress
Kaposi's sarcoma
Cutaneous Lesions:
Ewing sarcoma
Bacillary angiomatosis
Melanoma
Purpura
Osteosarcoma
Hematomas